Implementing CDC guidance for infant neuroimaging and infant and placental Zika virus testing
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

For very narrow results

When looking for a specific result

Best used for discovery & interchangable words

Recommended to be used in conjunction with other fields

Dates

to

Document Data
Library
People
Clear All
Clear All

For additional assistance using the Custom Query please check out our Help Page

i

Implementing CDC guidance for infant neuroimaging and infant and placental Zika virus testing

Filetype[PDF-181.50 KB]


Details You May Also Like

Details:

  • Corporate Authors:
    Centers for Disease Control and Prevention (U.S.)
  • Description:
    Based on maternal Zika virus exposure and laboratory test results.

    Notes:

    1. This tool summarizes general CDC guidance for the following scenarios. The tool only addresses live births. Please consult CDC* or your state or local health department for case-specific questions. Health departments should adapt CDC guidance depending on local capacity and circumstances.

    2. In all cases, infants with anomalies consistent with congenital Zika syndrome should also be evaluated for other etiologies of congenital anomalies.

    3. Infant serum and urine should be tested for Zika virus by Zika NAT, and infant serum for Zika virus IgM antibodies. If CSF is obtained, it can also be tested. Please refer to the published guidance for more information.

    4. Placental testing includes testing of formalin-fixed or formalin-fixed, paraffin-embedded placenta, umbilical cord, and fetal membranes by ZIKV RT-PCR. Microscopic evaluation of fixed tissues is conducted in selected cases. Please note that a positive RT-PCR result from placental testing cannot distinguish between maternal and fetal infection; therefore, a positive RT-PCR result from the placenta can confirm maternal Zika infection but cannot be used to confirm congenital Zika infection in the infant. Negative NAT results on placental tissue do not exclude maternal ZIKV since the duration of ZIKV persistence in the placenta is unknown and the samples evaluated may not reflect the placenta in its entirety. Please refer to the website for further guidance.

    CS267383-A

    placental-testing-guidance.pdf

  • Subjects:
  • Series:
    CDC's response to Zika
  • Document Type:
    Pamphlet (or booklet)
  • Collection(s):
  • Main Document Checksum:
  • Download URL:
  • File Type:

Supporting Files

  • No Additional Files
More +

You May Also Like

Checkout today's featured content at stacks.cdc.gov